Patent Issued for Allograft tolerance without the need for systemic immune suppression (USPTO 12178835).

Sinai Health System in Toronto, Canada, has been granted a patent (USPTO 12178835) for a method to achieve allograft tolerance without the need for systemic immune suppression. The patent focuses on genetically modifying cells to provide local immunosuppression at the transplant site in an allogeneic host. This approach aims to address the challenge of immune rejection in cell therapies, offering a potential solution to improve outcomes in transplantation. [Extracted from the article]